A targetable ALDH3A2-NRF2 axis mediates KEAP1-mutant tumour development via ferroptosis inhibition.
A novel NRF2 regulatory pathway is revealed and ALDH3A2 is suggested as a promising druggable target for KEAP1-mutant tumours by performing an aldehyde dehydrogenase 3 family shRNA screen.